Measurable residual disease (MRD) is an important biomarker in acute myeloid leukemia
(AML) that is used for prognostic, predictive, monitoring, and efficacy-response …

Several methodologies that rely on the detection of immunophenotypic or molecular
abnormalities of the neoplastic cells are now available to quantify measurable (“minimal”) …

Measurable residual disease (MRD; previously termed minimal residual disease) is an
independent, postdiagnosis, prognostic indicator in acute myeloid leukemia (AML) that is …

There is considerable interest in developing techniques to detect and/or quantify remaining
leukaemia cells termed measurable or, less precisely, minimal residual disease (MRD) in …

The past 40 years have witnessed major advances in defining the cytogenetic aberrations,
mutational landscape, epigenetic profiles, and expression changes underlying …

Quantification of measurable residual disease (MRD) provides critical prognostic information
in acute myeloid leukemia (AML). A variety of platforms exist for MRD detection, varying in …

Mounting evidence indicates that the presence of measurable (“minimal”) residual disease
(MRD), defined as posttherapy persistence of leukemic cells at levels below morphologic …

Importance Measurable residual disease (MRD) refers to neoplastic cells that cannot be
detected by standard cytomorphologic analysis. In patients with acute myeloid leukemia …

Technological advances in the laboratory have led to substantial improvements in clinical
decision making through the introduction of pretreatment prognostic risk stratification factors …

Prognostic factors determined at diagnosis are predictive for outcome whereas achievement
of morphological complete remission (CR) is still an important end point during treatment …